Emergent BioSolutions gets gov't order for BioThrax

Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the government was contemplating the contract. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.